Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03320603
Other study ID # OPTIPLEX 2
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 13, 2017
Est. completion date December 20, 2020

Study information

Verified date July 2021
Source Octapharma
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study is assessing the impact of an expert eCRF on the management of severe bleeding in the administration of Prothrombin Complex Concentrate in patients treated with oral anticoagulants and adherence to recommendations or experts' consensus


Recruitment information / eligibility

Status Completed
Enrollment 397
Est. completion date December 20, 2020
Est. primary completion date December 20, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult patients (= 18 years old) - Receiving oral anticoagulants (VKA or DOAC) - With a severe bleeding episode meeting at least one of the following criteria - External hemorrhage which cannot be controlled by usual means or - Hemodynamic instability: SBP < 90 mmHg or SBP decrease - 40 mmHg from usual SBP or mean BP < 65 mmHg or any sign of shock or - Patient requiring a hemostatic procedure in emergency: surgery, interventional radiology, endoscopy or - Need for transfusion of packed red blood cells or - Hemorrhage jeopardizing the vital or functional prognosis: e.g. intracranial hemorrhage, intraspinal hemorrhage, intraocular or retro-ocular hemorrhage, hemothorax, hemoperitoneum, retroperitoneal hemorrhage, hemopericardium, deep muscle hematoma or compartment syndrome, acute digestive hemorrhage, hemarthrosis. - Admitted in the participating emergency service - Accepting the collection of his/her own health-related data Exclusion Criteria: - Patient participating in another interventional study - Pregnant or nursing woman - Patient under supervision or legal guardianship

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Expert eCRF
An expert eCRF will be used to guide physicians during the management of patients treated with Vitamin K Agonist or Direct Oral Anticoagulant admitted in emergency units for severe bleeding.
Prothrombin Complex Concentrate
Prothrombin Complex Concentrate given as standard of care

Locations

Country Name City State
France Centre Hospitalier d'Avignon Avignon
France Centre Hospitalier Régional Universitaire de Besançon Hôpital Jean Minjoz Besançon
France Clinique Médipole Saint-Roch Cabestany
France Centre Hospitalier Universitaire de Caen Hôpital Côte de Nacre Service de Réanimation Caen
France Centre Hospitalier Universitaire de Caen Hôpital Côte de Nacre Service des Urgences Caen
France Centre Hospitalier Chalon-sur-Saône William Morey Chalon-sur-Saône
France Hôpitaux Civils de Colmar Colmar
France Clinique du Tonkin Lyon
France Hospices Civils de Lyon Centre Hospitalier Lyon-Sud Service de Réanimation Lyon
France Hospices Civils de Lyon Centre Hospitalier Lyon-Sud Service des Urgences Lyon
France Hospices Civils de Lyon Hopital Edouard Herriot Service des Urgences Lyon
France Centre Hospitalier Régional Metz-Thionville Hôpital Mercy Metz
France Centre Hospitalier Universitaire de Nantes Hôtel-Dieu Nantes
France Centre Hospitalier de Pau Pau
France Centre Hospitalier de Perpignan Perpignan
France Centre Hospitalier Universitaire de Reims Hôpital Maison Blanche Reims
France Centre Hospitalier Universitaire de Rennes Hôpital Pontchaillou Rennes
France Centre Hospitalier Universitaire de Rouen Hôpital Charles-Nicolle Rouen
France Centre Hospitalier Universitaire de Strasbourg Hôpital de Hautepierre Service de Réanimation Strasbourg
France Centre Hospitalier Universitaire de Strasbourg Hôpital de Hautepierre Service des Urgences Strasbourg
France Centre Hospitalier Universitaire de Strasbourg Nouvel Hôpital Civil Service des Urgences Strasbourg
France Hôpital d'Instruction des Armées Sainte-Anne Toulon
France Centre Hospitalier Universitaire de Toulouse Hôpitaux Purpan et Rangueil Toulouse
France Centre Hospitalier Régional Universitaire de Tours Hôpital Trousseau Tours
France Centre Hospitalier de Valence Valence
France Groupe Hospitalier de la Haute-Saône Site de Vesoul Vesoul

Sponsors (1)

Lead Sponsor Collaborator
Octapharma

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proper Use of PCC Proportion Proportion of patients for whom the rules of proper use of PCC have been respected 20 months
Secondary Time to Death Time to death 20 months
Secondary Survival Rate Survival rate 20 months
Secondary Proportion of Patients with Poor Outcome Proportion of patients with poor outcome: comparison of phase 1 and phase 2 20 months
Secondary Predictors of Poor Outcome Predictors or poor outcome. Potential predictors of poor outcome will be the time from first symptom to admission, the time from first symptom to Prothrombin Complex Concentrate administration, adherence to recommendations regarding proper use of Prothrombin Complex Concentrate, concomitant antiplatelets treatment, medical history or concomitant diseases (cardiac failure, coronary disease, renal failure, diabetes, severe COPD, cancer). For intracranial hemorrhages predictors will include the volume of intracranial hematoma. 20 months
Secondary Proportion of Patients with Seroconversion Proportion of Patients with Seroconversion 20 months